Aug 2026· Serican Journal of Medicine· 0 citations· 17 references
TL;DR
In conclusion, AR-V7-driven mitochondrial metabolic remodeling is central to enzalutamide resistance; future studies should dissect AR-V7–mitochondria regulatory nodes and optimize mitochondria-targeted combination strategies.
Abstract
Enzalutamide resistance in castration-resistant prostate cancer (CRPC) is frequently driven by androgen receptor splice variant 7 (AR-V7), a prognostic biomarker that lacks the ligand-binding domain and evades enzalutamide inhibition; however, the downstream metabolic networks sustaining resistant-cell survival remain incompletely understood. This review summarizes AR-V7 structural features, non-canonical transcriptional programs, and resulting mitochondrial dysfunction. AR-V7 occupies distinct chromatin-binding sites, preferentially activating genes involved in oxidative phosphorylation (OXPHOS), glutamine metabolism, and redox homeostasis while repressing tumor-suppressive metabolic genes. This dual transcriptional mode yields a bidirectional mitochondrial phenotype: hyperactive OXPHOS and enhanced antioxidant defense coexist with mitochondrial structural damage and ferroptosis evasion. Consequently, AR-V7-positive tumors exhibit high mitochondrial dependency, representing a targetable vulnerability. Preclinical strategies—including electron transport chain complex I inhibition, glutaminase blockade, copper ionophore-induced cuproptosis, and AR-V7-targeted degradation—show promise in enzalutamide-resistant models, but normal tissue toxicity, metabolic plasticity, dynamic AR-V7 expression, and lack of validated biomarkers remain translational obstacles.
In conclusion, AR-V7-driven mitochondrial metabolic remodeling is central to enzalutamide resistance; future studies should dissect AR-V7–mitochondria regulatory nodes and optimize mitochondria-targeted combination strategies.
Resistance to the androgen receptor inhibitor enzalutamide (ENZ) is a major barrier to durable control of advanced prostate cancer. Given the central role of metabolic reprogramming in tumour survival under therapeutic stress, we investigated whether ENZ resistance is associated with adaptive metabolic rewiring that...
Olivia Lee, Gio Fidelito, Qing Zhao et al.· Cell Death Discovery· 0 citations
These findings establish the UBR5-KDM5A-cAMP-PKA-SIRT3 axis as a central regulator of cisplatin resistance in TNBC and highlight KDM5A as a promising therapeutic target for combination treatment strategies.
Ming-Kai Gong, Fan Liang, Hu Wang et al.· Drug resistance updates· 0 citations
This study identifies a novel ‘PD-L1–ER stress–pyruvate–macrophage senescence’ axis as a key mechanism underlying primary resistance to ICB and proposes that targeting the PDK4/GLS-dependent pyruvate surge offers a promising therapeutic strategy to sensitize tumors to anti-PD-1 immunotherapy.
Wen-Xin Lian, Hui Yang, Yu-Qi Zhang et al.· Journal for ImmunoTherapy of...· 0 citations
Drug resistance remains the first and most significant barrier to long-term curative benefits in lung cancer patients. Traditional resistance mechanisms focused on oncogenic driver mutations are inadequate to explain reversible tumor phenotypic plasticity under therapeutic stress. Increasing evidence has placed mitocho...
Rui-Xuan Liu, Xin-Yao Wang, Ze-Tong Li et al.· Frontiers in Genetics· 0 citations
Findings establish Malonyl-CoA:ACP transacylase (MCAT), a Lauren subtype-associated gene encoding a key mitochondrial fatty acid synthesis (mtFAS) enzyme, as a metabolic switch that links ROS/P53-dependent cell death and therapeutic target for GC.
Yu-Fei Wang, Meng Zhu, Xin Yin et al.· Cell Death and Differentiati...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.